Invasion and migration is the hallmark of malignant tumors as well as the major cause for breast cancer death. The polypyrimidine tract binding, PTB, protein serves as an important model for understanding how RNA binding proteins affect proliferation and invasion and how changes in the expression of these proteins can control complex programs of tumorigenesis. We have investigated some roles of polypyrimidine tract binding protein 1 (PTBP1) in human breast cancer. We found that PTBP1 was upregulated in breast cancer tissues compared with normal tissues and the same result was confirmed in breast cancer cell lines. Knockdown of PTBP1 substantially inhibited tumor cell growth, migration, and invasion. These results suggest that PTBP1 is associated with breast tumorigenesis and appears to be required for tumor cell growth and maintenance of metastasis. We further analyzed the relationship between PTBP1 and clinicopathological parameters and found that PTBP1 was correlated with her-2 expression, lymph node metastasis, and pathological stage. This will be a novel target for her-2( + ) breast cancer. PTBP1 exerts these effects, in part, by regulating the phosphatase and tensin homolog-phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B (PTEN-PI3K/Akt) pathway and autophagy, and consequently alters cell growth and contributes to the invasion and metastasis.
2009). PTBP1 also has a role in determining mRNA localization in the cytoplasm (Cote et al., 1999) . Another important function of PTBP1 is its involvement in internal ribosome entry site mediated translation (Auweter & Allain, 2008) .
It has been found that PTBP1 is overexpressed in human epithelial ovarian tumors (He, Ee, Coon, & Beck, 2004; He et al., 2007) and glioblastomas compared with normal tissues. Knockdown of PTBP1 expression in tumor cell lines, such as A2780 (ovarian cancer) and PC-3M (prostate cancer), significantly impaired growth of tumor cells and their malignant properties (Jin, McCutcheon, Fuller, Huang, & Cote, 2000; Wang et al., 2008) . The expression levels of PTBP1 have been found to be elevated in brain tumors (Cheung et al., 2009; McCutcheon, Hentschel, Fuller, Jin, & Cote, 2004) , ovarian tumors (He et al., 2007) , and different malignant cell lines (Wang et al., 2008) . Furthermore, high expression of PTBP1 has been found to be associated with the aggressive behavior of several types of cancer, especially in glioma and ovarian tumors (Cheung et al., 2009; He et al., 2007) .
In our study, we investigated the role of PTBP1 in breast cancer. We found that PTBP1 was overexpressed in breast cancer tissues compared with normal tissues and breast cancer cell lines, which was accompanied by increased p-Akt and decreased phosphatase and tensin homolog (PTEN) expression. Meanwhile, we found that PTBP1 inducing the transition of the LC3BII to LC3BI is a significant event in autophagy.
Knockdown of PTBP1 expression substantially decreased tumor cell proliferation, migration, and invasion. Knockdown of PTBP1 inhibited breast cancer cell growth in nude mice. We further analyzed the relationship between PTBP1 and clinicopathological parameters. The analyzed parameters were tumor size, axillary lymph node metastasis (pN), estrogen receptor (ER), progesterone receptor (PR), pathological stage, and her-2. We found that PTBP1 was correlated with her-2 expression, lymph node metastasis, and pathological stage. Together, these results suggest that PTBP1 is involved in breast tumorigenesis and maybe a new target for breast cancer therapy. (NIH publication no. 80-23, revised 1996) and approved by the Animal Ethic Committee of the China Medical University.
| MATERIALS AND METHODS

| Clinical samples and mice
| Cell culture
Normal human breast epithelial cell line MCF-10A was cultured in Mammary Epithelial Cell Growth Medium (Lonza No. CC-3150) with 100 ng/ml cholera toxin (2-mg vials; Sigma No. C-8052, Grand Island). 
| Western blot assay
Cells and tissues were lysed in a radio immunoprecipitation assay (RIPA) lysis buffer supplemented with protease inhibitors (Roche). Total protein extracts were separated by 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to a polyvinylidenefluoride (PVDF) membrane (Millipore). The membranes were blocked in 5% skimmed milk for 1 hr and incubated with anti-PTBP1 (1:1,000; Abcam), anti-PTEN (1:1,000; Abcam), anti-Akt (1:1,000; Abcam), antip-Akt (1:1,000; Abcam), anti-LC3B (1:1,000; Abcam), anti-Flag (1:2,000; ShangHai Ruixing), anti-Actin (1:5,000; Abcam, as a loading control), and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:15,000; KangChen, China, as a loading control) antibodies. Appropriate primary antibodies were added at 4°C overnight. Appropriate secondary antimouse and antirabbit antibodies were added for 2 hr at room temperature. Finally, for detection of the proteins, an enhanced chemiluminescence (ECL) chemiluminescence system (Thermo Fisher Scientific/Thermo pierce) was used. 
| Transwell migration and invasion assay
| Lentiviral infection
PTBP1 short hairpin RNAs (PTBP1-shRNA) and control lentivirus were obtained from Shanghai Genechem Co., Ltd. The PTBP1-shRNA 1# sequence was 5′-TCGTCAAAGGATTCAAGTT-3′; the PTBP1-shRNA 2# sequence was 5′-CAACGTCAAGTACAACAAT-3′; the PTBP1-shRNA 3# sequence was 5′-AGCCCATCTACATCCAGTT-3′
and the shRNA control sequence was 5′-TTCTCCGAACGTGTCA CGT-3′. MDA-MB-231 cells were seeded into 12-well plates overnight.
Then, the cells were infected with PTBP1-shRNA 1#, PTBP1-shRNA 2#, PTBP1-shRNA 3# and control lentivirus following the manufacturer's guidelines (GeneChem, China); 5 μg/ml puromycin (Sigma) was added to the medium to select infected cells. 5 days after infection, fluorescence microscopy was used to detect the lentiviral infection rate. 
| RNA isolation and quantitative Real time-Polymerase chain reaction
| Clone formation
PTBP1-shRNA and control lentiviral infection cells were seeded in matrigel (BD) precoated six-well plates. After 14 days, the cells were photographed and counted by an inverted microscope.
| Immunohistochemical staining
Paraffin sections cut from paraffin-embedded breast cancer tissues were dewaxed and rehydrated. Immunohistochemical staining assay was used to detected the expression of PTBP1 in all tumor sections with the PTBP1 antibody (1:250; Abcam) and ElivisionTMplus (Maixin Biotechnology Co., Ltd, China). Then the nucleus was stained with hematoxylin (Maixin Biotechnology Co., Ltd). After hydration and transparent, the sections were sealed with neutral resins and photographed. 
| Knockdown of PTBP1 expression inhibits breast cancer cell proliferation in vivo
To show the effect of decreased PTBP1 expression levels in breast cancer cells in vivo, we generated xenografts in nude mice.
MDA-MB-231 cell infected with lentivirus expressing PTBP1 shRNA or control shRNA were subcutaneously injected into five nude mice in total. The first day of lentiviral shRNA injection was recorded as day 0 and after 3 weeks the tumor size was measured every 3 days.
At the 36th day, these mice were killed and tumor weight and volume (Figure 5d ). These data suggested that PTBP1 knockdown induced cell growth inhibition could be partially mediated by an altered PTEN/Akt signal pathway.
Knockdown of PTBP1 was reported to lead to autophagy in colorectal cancer. In our study, we found that knockdown of PTBP1 induced the transition of the LC3BI to LC3BII in cancer cells ( Figure   5e ) and overexpression of PTBP1 reduced the transition of the LC3BI to LC3BII (Figure 5f ), which was a significant event in autophagy. To investigate whether PTBP1 can affect the PTEN/Akt signal pathway in breast cancer samples, we examined paired samples from 137 breast cancer patients by western blot analysis. The levels of PTBP1 and p-Akt were high (Figure 6a) . The relationship between PTBP1 and p-Akt was significant (Figure 6b ).
| DISCUSSION
Breast cancer is one of the most common malignancies in middle aged and elderly women globally, representing 1.20 million cases annually in women worldwide (Chen et al., 2016) . In recent years, significant progress has been made in the treatment of breast cancer (d) The overexpression of PTBP1 decreased the expression of PTEN compared with the controls using western blot assay. GADPH was used as a loading control. (e) To validate the effct of PTBP1 on autophagy, the expression level of LC3BI and LC3BII was examined by western blot analysis. Knockdown of PTBP1 induced the transition of the LC3BI to LC3BII. GADPH was used as a loading control. (f) Overexpression of PTBP1 reduced the transition of the LC3BI to LC3BII using western blot analysis. GADPH was used as a loading control. GADPH, glyceraldehyde-3-phosphate dehydrogenase; p-AkPTBP1, polypyrimidine tract binding protein 1; PTEN, phosphatase and tensin homolog as more basic and clinical studies were conducted, and the study on breast cancer treatment has become one of the hot topics of cancer research (Cote et al., 1999) . Invasion and migration is the hallmark of malignant tumors as well as the major cause for breast cancer death (Auweter & Allain, 2008; He et al., 2004) . However, the development details and underlying pathological mechanisms remain to be determined. The PTB, also known as PTBP1 or polypyrimidine tract binding protein 1 (hnRNPI), is one of the most investigated RBP in vertebrates involved in almost all steps of mRNA regulation during tumorigenesis, due to its RNA-binding activity. PTBP1 is generally described as a widely expressed factor in adult tissues, and accordingly it is present in most of the cell lines studied (Wang et al., 2008) . However, its amount can strongly vary from tissue to tissue or depending on the cellular differentiation states. The expression levels of PTBP1 have been found to be elevated in brain tumors (He et al., 2004; He et al., 2007) , ovarian tumors (Jin et al., 2000) , and different malignant cell lines (McCutcheon et al., 2004) .
Furthermore, high expression of PTBP1 has been demonstrated to be associated with the aggressive behavior of several types of cancer, especially in glioma and ovarian tumors (He et al., 2007; Jin et al., 2000) . Thus, PTBP1 plays an important role and has different functions in tumorigenesis by regulating the amounts of target genes associated with malignancy.
Our data revealed that PTBP1 was significantly higher in breast cancer tissues and breast cancer cell lines compared with normal breast tissue and normal human breast epithelia, as demonstrated by the immunohistochemistry and western blot analysis (Figure 1) , consistent with previous studies (He et al., 2014; He, Yuan, & Yang, 2015) . A recent study found that PTBP1 is overexpressed in ovarian tumors and colorectal cancer (He et al., 2007; Takahashi et al., 2015) indicating that PTBP1 is closely associated with the pathogenesis and development of cancer. However, the correlation of PTBP1 with clinical characteristics has not been clarified. Further analysis was performed to investigate the relationship between PTBP1 expression in breast cancer tissues and clinicopathological characteristics of cancer. The results revealed that the level of PTBP1 expression in breast cancer tissue was positively correlated with her-2, lymph node metastasis, and pathological stage ( Table 1) .
The mechanism underlying the tumor promoting function of PTBP1 in breast cancer was further studied by reducing PTBP1 expression in the human breast cancer cell lines. As reported previously, PTBP1 has been involved in several biological functions crucial for cancer development, including proliferation (Cheung et al., 2009; He et al., 2007; He et al., 2014; Sugiyama et al., 2016) , migration and invasion (Cheung et al., 2009; He et al., 2007; He et al., 2014) . In our study, we discovered that knockdown of PTBP1
significantly inhibited breast cancer cell proliferation in vitro.
Similarly, recent study has found that PTBP1 downregulation suppressed cell proliferation in colorectal cancer in vitro (Takahashi et al., 2015) . Meanwhile, we found that PTBP1 knockdown attenuated the migration and invasion of breast cancer cells, whereas overexpression of it enhanced these malignant properties. Consistent with our findings, PTBP1 knockdown inhibited the migration of glioma cells (Cheung et al., 2009) , the migration and invasion of ovarian tumor cells (He et al., 2007; He et al., 2015) . when PTBP1 is overexpressed by western blot. Furthermore, we detected the expression level of PTEN and found that it was downregulated by PTBP1. Consistent with our findings, PTBP1 is reported to mediate the PTEN/Akt signal pathway in bladder cancer (Takai et al., 2017) .
Autophagy is a highly conserved physiological phenomenon in most eukaryotic cells and a cellular material recycling mechanism that is dependent on the lysosomes. Autophagy is closely related to the development of malignant tumors. In a variety of adverse circumstances, autophagy protects survival of tumor cells as an emergency mechanism, whereas initiation of autophagic cell death clears the tumor cells. Knockdown of PTBP1 induces the transition of the LC3BI to LC3BII in cancer cells, which can prompt autophagy.
Mechanistically, the LC3BII/LC3BI ratio was remarkably increased when PTBP1 silenced and significantly decreased when PTBP1 overexpressed using western blot analysis. Consistent with our findings, PTBP1 is reported to mediate the LC3B isoform switching from LC3BII to LC3BI in bladder cancer (Takai et al., 2017) . These results strongly suggested that PTBP1 positively regulated the proliferation of breast cancer cells through the combination regulation of PTEN/Akt signal pathway and the transition of the LC3BI to LC3BII in autophagy.
In conclusion, it is our novel discovery that PTBP1 is upregulated 
